In conclusion, somatic mutations associated with resistance to imatinib are acquired in CML-CP de novo, thus early mutation detection is highly required to prevent progression because several therapeutic options exist for cases with mutated KD of BCR-ABL1. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.